Harbour BioMed reported positive Phase 2 interim results for HBM9378/WIN378 in asthma, showing sustained improvements in FEV1, FeNO and blood eosinophils through Week 24 after a single dose.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.